anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a receipt of gypenoside lipidosome consisting of sterol. The receipt comprises gypenoside, a phosphatide material and the sterol. The invention further discloses a preparation method of the gypenoside lipidosome consisting of the sterol. A preparation form of the lipidosome can be a freeze-drying injection, an injection, a transdermal preparation, aerosol, oral liquid, a solution, an eye-drops preparation, a tablet or a capsule. The gypenoside lipidosome has important treatment effects for hyperlipidemia and cardiovascular and cerebrovascular diseases, and furthermore, has positive treatment and prevention effects for tumor, hepatitis, gastritis, gastric and duodenal ulcer, gastroptosis, stomatitis, diabetes mellitus, astriction, haemorrhoids, asthma, cephalagra, acne, stain, gall-stone, numbness of limbs, pachulosis, male infertility, recession of sexual functions, fatness, white hair and baldness. Furthermore, the physical strength of a human body can be enhanced, the immunity of the organism is improved, the state of fatigue can be relieved, the sleep quality can be obviously improved, the appetite can be whetted, and the senescence can be delayed.
PURPOSE: Muscle quality is more important than muscle mass for assessing physical function. Computed tomography (CT) is used to evaluate intramuscular fatty infiltration. The mid-thigh quadriceps CT attenuation values (CTV) expressed in Hounsfield units (HU) negatively correlate with physical function. Patients with hip osteoarthritis (HOA) have lower extremity muscle atrophy, including decreased cross-sectional area (CSA), CTV, and muscle strength. Using preoperative CT images, we investigated the association between mid-thigh quadriceps CSA, CTV, and postoperative outcomes in patients with HOA.
METHODS: This study included 62 patients who had unilateral HOA (62 hips) and underwent total hip arthroplasty (THA). We investigated the association between preoperative and postoperative Japanese Orthopaedic Association (JOA) hip scores, 12-item Short Form survey (SF-12), mid-thigh quadriceps CSA, and CTV.
RESULTS: The mean age was 64.7 ± 10.1 years, with 15 men (24.2%), and the mean body mass index was 24.3 ± 4.3 kg/m2. Secondary HOA was present in 79.0% of patients. The mean CSA and CTV of the mid-thigh quadriceps on the operative side were 38.8 ± 9.8 cm2 and 40.3 ± 7.8 HU, respectively. Multiple regression analyses adjusted for age and sex showed that preoperative mid-thigh quadriceps CSA was not associated with preoperative and postoperative JOA hip scores or SF-12. The preoperative mid-thigh quadriceps CTV was associated with the postoperative JOA hip score in the gait ability domain and SF-12 in the physical component summary domain.
CONCLUSION: Preoperative muscle quality is associated with postoperative outcomes in patients who have HOA regardless of age and sex.
Nano silver fluoride solution (Prepared in Nanotech Co., Egypt) based on silver nanoparticles, chitosan and fluoride. Each tooth will receive two drops of NSF with a micro brush, equivalent to a dose of 10 mg of the solution.
Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus, causes severe diarrhea in neonatal piglets, which is associated with a high mortality rate. Thus, developing effective and safe vaccines remains a top priority for controlling PEDV infection. Here, we designed two lipid nanoparticle (LNP)-encapsulated mRNA (mRNA-LNP) vaccines encoding either the full-length PEDV spike (S) protein or a multiepitope chimeric spike (Sm) protein. We found that the S mRNA-LNP vaccine was superior to the Sm mRNA-LNP vaccine at inducing antibody and cellular immune responses in mice. Evaluation of the immunogenicity and efficacy of the S mRNA vaccine in piglets confirmed that it induced robust PEDV-specific humoral and cellular immune responses in vivo. Importantly, the S mRNA-LNP vaccine not only protected actively immunized piglets against PEDV but also equipped neonatal piglets with effective passive anti-PEDV immunity in the form of colostrum-derived antibodies after the immunization of sows. Our findings suggest that the PEDV-S mRNA-LNP vaccine is a promising candidate for combating PEDV infection.IMPORTANCEPorcine epidemic diarrhea virus (PEDV) continues to harm the global swine industry. It is important to develop a highly effective vaccine to control PEDV infection. Here, we report a PEDV spike (S) mRNA vaccine that primes a potent antibody response and antigen-specific T-cell responses in immunized piglets. Active and passive immunization can protect piglets against PED following the virus challenge. This study highlights the efficiency of the PEDV-S mRNA vaccine and represents a viable approach for developing an efficient PEDV vaccine.
<P>PROBLEM TO BE SOLVED: To provide a paste sheet for cutaneous administration, improved in feeling of use and usability by inhibiting pyroligneous acid composition from remaining on the skin and from transferring to a separation film, and keeping the primary effect of the pyroligneous acid for long time, and a manufacturing method for it.  <P>SOLUTION: In this paste sheet for cutaneous administration, a pressure sensitive adhesive layer composed of pyroligneous acid and hydrous gel is formed on a base material and the pressure sensitive adhesive layer is covered with the separation film. Preferably the base material is a laminated base material of a non-woven fabric/air impermeable film or a non-woven fabric/air impermeable film/non-woven fabric. The above sheet is formed by superposing the base material and the separation film between two rollers disposed at a designated space. A first liquid containing pyroligneous acid and a second liquid containing a polyacrylate and a crosslinking agent are mixed, and then dropped in the superposition place to form a gel-like liquid pool. With rotation of two rollers, a gel-like pressure sensitive adhesive layer of a designated thickness is held between the base material and the separation film to manufacture the above paste sheet.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
T2 Formulation Regimen A (T2-A) TAK-385, 120 mg tablet (80 mg + 40 mg tablets), orally, under fasted conditions, T4 Formulation C Regimen D (T4C-D) TAK-385, 120 mg tablet, orally, under fasted conditions, and T4 Formulation C Regimen E (T4C-E) TAK-385, 120 mg tablet, orally, under fed conditions. There were 6 randomized sequences. Study medication was administered as a single dose on Days 1, 11 and 21. There was 10-day washout period between each dose.
A new process to increase light transmission in biological tissue has been developed. The technique involves temporarily replacing tissue water with a fluid that has a refractive index closer to that of inter/intra cellular components. Subsequently, the amount of index mis-match between these components and the fluid environment is temporarily decreased. This lowers the amount of random reflection and refraction which also reduces light scattering. In addition, the infrared absorption is reduced when the fluid has a lower absorption coefficient than water. Furthermore, this process is reversible; thus creating a transient window to enhance light transmission for therapeutic and/or diagnostic applications.
The field of the present invention is the field of anti-angiogenic cancer therapy. Efforts are needed to reduce or overcome resistance of cancer to anti-angiogenic therapies, such as therapies based on the receptor tyrosine kinase (RTK) inhibitor sunitinib. It is hence an object of the present invention to provide an agent that can be combined with an anti-angiogenic therapy in order to reduce or overcome resistance to the anti-angiogenic therapy. The present invention thus relates to a pharmaceutical composition or set comprising an apelin antagonist and/or apelin receptor antagonist, and an angiogenesis inhibitor. The angiogenesis inhibitor is an RTK inhibitor, preferably sunitinib. The apelin antagonist can be an anti-apelin antibody. The apelin receptor antagonist can be an apelin peptide analogue or an anti-apelin-receptor antibody. Furthermore, methods of cancer treatment, especially breast or lung cancer treatment, based on an apelin antagonist and/or apelin receptor antagonist, and an angiogenesis inhibitor are disclosed.
FIELD: medicine; prophylaxis of professional skin diseases; may be used in mining industry, in production of graphite and graphite-made articles, space research, in production of printing tapes for typewriters and electrodes widely using carbon black. SUBSTANCE: existing ointments and pastes (hydrophilic and hydrophobic ones) for protecting hand skin do not possess anticancerogenic and desensibilizing effect. Inventive novelty resides in additional introduction of α 30-% tocopherol and sodium phusidin at the following ratio of components, wt.-%: ascorbic acid, 1.0-3.0; α 30-% tocopherol, 1.0-3.0; lanolin, 29.0-31.0; peach-kernel oil, 290.-31.0; sodium phusidin, 3.0-5.0; distilled water, the balance. Use of preparation prevents pustules on hand skin and protects it against cancerogenic effect of hydrocarbons contained in petroleum and coal. EFFECT: higher efficiency. 1 tbl
The eligibility of infants, i.e. infants who meet the criteria for inclusion and exclusion (i.e infants at high-risk for CP) will be evaluated by the Neonatology team and the recruitment will be done after discharge from Neonatal Intensive Care Unit (NICU) during the follow up performed by infants previously enrolled in the first observational phase (aimed to identify infants at high risk for CP) and will begin with the signing of the participation agreement by the parents. The study is designed as randomized clinical trial. Recruited infants will be randomized in two groups: CareToy intervention vs Infant Massage. All infants will perform the home based and family centered early intervention according to their allocation group for 8 weeks. Before (T0), after the intervention period (T1) and in follow up (at T2, 8 wks after T1 and at 18 mths of post term age) all infants will be evaluated with standardized scales and questionnaires in order to evaluate the effects of EI on motor, cognitive and visual development and parent-infant interaction. Moreover the sleep organization, before and after the intervention, will be studied using actigraphs. The sample size has been calculated on the basis of the primary outcome measure (Infant Motor Profile).
Provided herein are nucleic acid molecules, proteins, compositions and methods for treating brain cancer in a subject. In some embodiments, the compositions comprise cancer antigens hTERT, WT-1, and PSMA. In some embodiments, the compositions also comprise an adjuvant. The methods comprise administering to a subject in need thereof the cancer antigens. According to certain embodiments, the methods further involve administering the adjuvant and an anti-PD-1 antibody. In certain embodiments, the methods further comprise administering radiation therapy and/or a chemotherapeutic agent. In certain embodiments, the methods are clinically proven safe, clinically proven effective, or both.
PROBLEM TO BE SOLVED: To obtain the subject new compound comprising a specific indoline compound and having excellent inhibitory actions on activated blood coagulation factor X and useful as a therapeutic or a prophylactic agent for blood coagulating diseases. SOLUTION: This compound is represented by formula I (R1 is H, a 1-6C alkyl or the like; R2 is a 3-10C cycloalkyl or the like; R3 and R4 are each H, a halogen or the like; A is a single bond a 1-4C alkylene or the like; n is 1 or 2), e.g. 2-(7-amidinonaphthalen-2-yl)-1-ethanesulfonyl-5-(piperidin-3-yloxy)ind oline dihydrochloride. The compound represented by formula I is obtained by reacting a compound represented by formula II with alcohols in the presence of an acid (e.g. hydrogen chloride) in an inert solvent (e.g. dichloromethane), preferably at 0-50 deg.C for 1-15 h, providing an iminoether compound and then carrying out an ammonolysis of the resultant iminoether compound in the presence of ammonium ion in an inert solvent at pH 7-9, preferably at 0-50 deg.C for 1-15 h.
Standardized lens photography with centralized grading of photographs has been used in clinical trials and epidemiologic studies of cataract. While photographic grading systems have been shown to be reliable, they are too expensive and complex to use in many studies. For some large studies, especially those with many centers or those in which lens changes are of secondary concern, it would be useful to have a simple clinical lens grading system that is reliable and that can be used with minimal training of examiners. Several clinical lens grading systems have been developed and found to be reliable in the hands of dedicated lens researchers, but the systems have been difficult for other ophthalmologists to use reliably.

The Age-Related Eye Disease Study (AREDA) has developed a simplified clinical cataract grading system to assess the severity of nuclear, cortical and posterior subcapsular cataracts, the 3 main types of age-related cataract. The system is designed to require minimal examiner training for persons already proficient in the use of the slit lamp. A total 150 participants with cataracts of varying severity, who are already participating in other NEI protocols, will be recruited to evaluate the reliability of the system. After being dilated, each participant will have a lens grading performed independently by 2 examiners. To provide information on the validity of the clinical gradings, lens photographs will be taken and graded using the detailed AREDS system for grading photographs. The data will allow us to evaluate (1) the agreement between the AREDS clinical lens grading system and the AREDS photographic system of grading lens opacities, and (2) the agreement on assessment of cataract severity among opthalmologists (with varying subspecialty) using the AREDS clinical lens grading method.
The present invention relates to sulfonamide derivatives of formula in which R1, R2, R4, R5 and R6 have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmaceutically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and inhibit bone resorption by osteoclasts. They are suitable, for example, for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example of osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula (I), their use, in particular as pharmaceutical active ingredients, and pharmaceutical preparations comprising them. 18 claims
Participants receive a total of three visits (one evaluation/pre-treatment visit and 2 treatment visits) that last 75 minutes each over 4 weeks. Sessions/visits are spaced 1 week apart and will be delivered remotely.
We will equip several local advanced life support ambulances with a low cost video laryngoscope for a total of 12 months. We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods including first pass intubation success, total success rate for intubation, and complications (need for surgical airway, rescue device, need to revert from KVL to DL, etc.). Please see the attached protocol page for additional details.
Participants from birth to \< 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days. Participants aged ≥ 6 years to \< 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. These nerves are then "cleaned up" to be rerouted and connected to smaller nerves that control individual muscles. The connection to nerves that run into muscles is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 2 - 4 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain.
PURPOSE:To provide a transcutaneous absorbefacient containing extract of crude drugs such as SHOZUKU (fruit of Elettoria cardamomum), SHOUKYOU (rhizome of Zingiber officinale), OUBAKU (bark of Phellodendron amurense) and KEIHI (bark of Cinnamomum cassia). CONSTITUTION:Crude drugs such as SHOZUKU, SHOUKYOU, OUBAKU or KEIHI are dried, crushed and immersed in 10 pts. (based on 1 pt. of the crude drug) of a cold solvent such as acetone, ether, ethyl acetate or water for 3 days, and the solvent extraction process is repeated thrice. The extract is filtered and then concentrated in vacuum at <=40 deg.C and the obtained dried extract is used as a component of the objective agent. Acetone extract especially has excellent transcutaneous absorbability and the agent is used in the form of a liquid spray, lotion, ointment, cream, aerosol, poultice, tape, etc. Examples of the agent increasing the drug action by the use of the above agent are anti- inflammatory, antihistaminic, sulfamides, antibiotic substance, antimycotic agent, anti-malignant tumor agent, narcotic agent, psychotropic agent, etc.
Pregnancy Category X: Fluvastatin is contraindicated in women who are or may become pregnant [see Contraindications (4)].

Lipid-lowering drugs are contraindicated during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Serum cholesterol and triglycerides increase during normal pregnancy. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy.

There are no adequate and well-controlled studies of use with fluvastatin during pregnancy. Rare reports of congenital anomalies have been received following intrauterine exposure to other statins. In a review2 of about 100 prospectively followed pregnancies in women exposed to other statins, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed the rate expected in the general population. The number of cases is adequate only to exclude a 3- to 4-fold increase in congenital anomalies over background incidence. In 89% of prospectively followed pregnancies, drug treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. 

Teratology studies with fluvastatin in rats and rabbits showed maternal toxicity at high dose levels, but there was no evidence of embryotoxic or teratogenic potential [see Nonclinical Toxicology (13)]. 

Fluvastatin should be administered to women of childbearing potential only when such patients are highly unlikely to conceive and have been informed of the potential hazards. If a woman becomes pregnant while taking fluvastatin capsules, the drug should be discontinued and the patient advised again as to the potential hazards to the fetus.
In the intensive care unit (ICU), acute respiratory failure is a common problem. Airway management in critically ill patients usually requires endotracheal intubation after rapid sequence induction. Induction of anesthesia is a well known cause of dramatic changes in respiratory mechanics and gas exchange. Moreover, when the intubation is for respiratory failure, the underlying pathology increases these modifications. The reduction in lung volume results in a deep hypoxemia after intubation. Moreover, mechanical ventilation applied on a collapsed lung increases the risk of ventilator induced lung injury. Recruitment maneuver, which consists of a transient increased in inspiratory pressure, decreases anesthesia-induced lung collapse and hypoxemia. During early acute respiratory failure, RM increases oxygenation and lung volume and may reduce lung oedema. Some authors have suggested the potential benefit of an early RM after induction of anesthesia in operating room. To date, no study has evaluated the short term effect of a recruitment maneuver performed early after intubation in critically ill patients. Therefore, our aim was to ascertain whether RM, performed immediately after intubation, is safe and more effective at reducing hypoxemia than usual management, in hypoxemic patients requiring intubation for invasive ventilation in the ICU.
Post-vaccination infections, termed breakthrough infections, occur after the virus infection overcomes the vaccine-induced immune barrier. During the early stages of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron wave, high serum-neutralizing antibody titers against the Omicron variant were detected in individuals with breakthrough infections as well as those who received a third vaccine dose (i.e., booster recipients). Additionally, these cases indicated that Omicron antigens triggered an immune response that differed from that triggered by the vaccine strain before analysis of the effectiveness of new vaccines updated for the Omicron variants. Moreover, the magnitude and breadth of neutralizing antibody titers induced by breakthrough infections are correlated with the upper respiratory viral load at diagnosis and the duration between vaccination and infection, respectively. Unlike booster vaccine recipients, patients with breakthrough infections have varying durations between vaccination and infection. Accordingly, optimal booster vaccination intervals may be estimated based on the cross-neutralizing antibody response induced over time. Examination of breakthrough infection cases has provided valuable insights that could not be yielded by only examining vaccinated individuals alone. These insights include estimates of vaccine-induced immunity against SARS-CoV-2 variants and the various factors related to the clinical status. This review describes the immune response elicited by breakthrough infections; specifically, it discusses factors that affect the magnitude and breadth of serum antibody titers as well as the appropriate booster vaccination strategy. This review provides key aspects that could contribute to developing next-generation COVID-19 vaccines through breakthrough infection cases.
Pharmacotherapy will be performed using α1-blockers and 5α-reductase inhibitors in accordance with the EAU recommendations. Thus, patients with a prostate size smaller than 40mL will be treated with 0.4 mg tamsulosin once daily, while patients with larger prostates will be treated with 0.4 mg tamsulosin plus 0.5 mg dutasteride once daily during the complete study follow-up.
Healthy male or female children of 3 or 4 years of age, who were previously vaccinated with 3 doses of Infanrix™ and Polio™ vaccines in the German household contact study (APV-039), additionally received 1 booster dose of Boostrix™ Polio vaccine co-administered with Priorix™ vaccine at Day 0. Boostrix™ Polio vaccine was administered intramuscularly in the deltoid muscle of the left arm, while Priorix™ vaccine was administered subcutaneously in the deltoid region of the right arm or as an intramuscular injection into the deltoid muscle of the right arm.
Subjects will receive 30mg of Duloxetine for blinded period 1 (first 4 week treatment period) and 30mg of Duloxetine plus 30mg Placebo for blinded period 2 (additional 4 weeks treatment period). After this, subjects will be unblinded and receive routine clinical care for follow up phase (up to 52 weeks).